Loading…
Agios Pharmaceuticals, Inc. is projected to rise to $51.48 by 2027, a +25% move from its current price of $41.23. AGIO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $39.81 | $41.23 | $42.70 | 0.00% |
| Jul 15 | $39.24 | $41.23 | $43.32 | 0.00% |
| Jul 16 | $38.80 | $41.23 | $43.81 | 0.00% |
| Jul 17 | $38.44 | $41.23 | $44.22 | 0.00% |
| Jul 18 | $38.13 | $41.23 | $44.59 | 0.00% |
| Jul 19 | $37.84 | $41.23 | $44.92 | 0.00% |
| Jul 20 | $37.58 | $41.23 | $45.23 | 0.00% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $37.58 | $41.23 | $45.23 | 0.00% |
| Week 2 | $36.17 | $41.23 | $47.00 | 0.00% |
| Week 3 | $35.12 | $41.23 | $48.41 | +0.01% |
| Week 4 | $34.26 | $41.23 | $49.63 | +0.01% |
| Week 5 | $33.52 | $41.23 | $50.72 | +0.01% |
| Week 6 | $32.86 | $41.23 | $51.74 | +0.01% |
| Week 7 | $32.27 | $41.24 | $52.69 | +0.01% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company that discovers and develops medicines in the field of cellular metabolism in the United States.
Its lead product PYRUKYND (mitapivat) is an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia.
In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
The company is categorized under Healthcare.
AGIO is trading at $44.01 with a market cap of $2.62B and a market rank of 1869.
The near-term price outlook is reflected in the 2026 forecast: min $24.43, avg $44.01, max $55.21, with sentiment NEUTRAL.
From 2027 onward, the forecast turns bullish with rising averages and higher ROI, including 2027 avg $54.77 (ROI 24.4%), 2028 avg $67.92 (ROI 54.3%), 2029 avg $90.52 (ROI 105.7%), 2030 avg $118.57 (ROI 169.4%), 2031 avg $130.06 (ROI 195.5%), 2032 avg $146.97 (ROI 233.9%), 2033 avg $160.94 (ROI 265.7%), 2034 avg $168.48 (ROI 282.8%), 2035 avg $216.79 (ROI 392.6%), with continued bullish momentum into 2040 (avg $363.70, ROI 726.4) and 2050 (avg $877.43, ROI 1893.7).
A major floor 52.1% below — a decisive break under it would weaken the trend.
The nearest floor, 35.7% below — buyers have tended to step in here.
The nearest ceiling, 6.7% above — a clean break opens room to run.
A major ceiling 32.8% above — clearing it would confirm fresh momentum.
Key AGIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AGIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $41.64 | Sell | $41.29 | Sell |
| MA 10 | $39.59 | Buy | $39.73 | Buy |
| MA 20 | $36.41 | Buy | $37.10 | Buy |
| MA 50 | $31.47 | Buy | $33.41 | Buy |
| MA 100 | $30.59 | Buy | $31.81 | Buy |
| MA 200 | $31.84 | Buy | $31.93 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 69.35 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 101.05 | Buy |
| Williams %R (14) | -31.20 | Info |
| MACD (12,26,9) | 0.51 | Buy |
| ROC (12) | 15.85 | Buy |
| Bollinger %B (20,2) | 0.79 | Neutral |
| Stochastic %K (14) | 68.80 | Neutral |
| TRIX (15) | 1.23 | Buy |
| Awesome (5,34) | 8.53 | Buy |
| Ultimate (7,14,28) | 71.17 | Sell |
| Momentum (10) | 5.03 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 43.94 | Sell |
| ADX (14) | 38.04 | Buy |
| ATR (14) | 1.08 | Info |
The 30-day technical picture is bullish. RSI14 is 80, signaling strong near-term momentum.
Key moving averages show SMA50 at $30.42 and SMA200 at $31.78, with a near-term support at $26.51 and resistance at $44.01.
The 30-day range spans from $34.51 to $56.12, highlighting upside potential within the current volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $24.43 | $41.23 | $52.09 | 0% | Neutral | |
| $39.91 | $51.48 | $70.86 | +25% | Bullish | |
| $47.95 | $64.17 | $92.45 | +56% | Bullish | |
| $62.03 | $85.62 | $127.80 | +108% | Bullish | |
| $78.74 | $111.70 | $171.73 | +171% | Bullish | |
| $85.43 | $124.28 | $196.04 | +201% | Bullish | |
| $94.90 | $141.36 | $228.16 | +243% | Bullish | |
| $101.36 | $154.37 | $254.38 | +274% | Bullish | |
| $105.37 | $163.93 | $275.31 | +298% | Bullish | |
| $130.96 | $207.95 | $355.43 | +404% | Bullish | |
| $203.87 | $355.80 | $654.27 | +763% | Bullish | |
| $417.45 | $862.85 | $1,762.57 | +19.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $24.43 | $41.23 | $50.85 | +0.00% |
| August 2026 | $35.19 | $41.85 | $51.33 | +1.50% |
| September 2026 | $34.36 | $41.24 | $51.30 | -1.46% |
| October 2026 | $35.06 | $42.41 | $53.38 | +2.83% |
| November 2026 | $34.81 | $42.38 | $53.88 | -0.06% |
| December 2026 | $33.15 | $40.61 | $52.09 | -4.19% |
Click any year to see its month-by-month AGIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Agios Pharmaceuticals, Inc.'s 2026 outlook centres on $41.23, within a $24.43 to $52.09 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, AGIO could reach as high as $70.86, with a base case around $51.48 and support toward $39.91 — roughly +25% from $41.23. Momentum favours further upside here.
Expect AGIO to range from $47.95 to $92.45 through 2028. The $64.17 average target implies a +56% move from current prices. That is up +25% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The AGIO price prediction for 2029 points to an average of $85.62 (low $62.03, high $127.80) — a potential gain of +108% on today's $41.23. Momentum favours further upside here.
In 2030, AGIO is projected to trade between $78.74 and $171.73, averaging $111.70 — a potential gain of +171% from today's $41.23. That is up +30% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Agios Pharmaceuticals, Inc.'s 2031 outlook centres on $124.28, within a $85.43 to $196.04 range. That is up +11% on the projected 2030 average. That marks a +201% change versus current levels. Momentum favours further upside here.
By 2032, AGIO could reach as high as $228.16, with a base case around $141.36 and support toward $94.90 — roughly +243% from $41.23. Buyers look set to stay in control over this stretch.
Expect AGIO to range from $101.36 to $254.38 through 2033. The $154.37 average target implies a +274% move from current prices. That is up +9% on the projected 2032 average. Momentum favours further upside here.
The AGIO price prediction for 2034 points to an average of $163.93 (low $105.37, high $275.31) — a potential gain of +298% on today's $41.23. Buyers look set to stay in control over this stretch.
In 2035, AGIO is projected to trade between $130.96 and $355.43, averaging $207.95 — a potential gain of +404% from today's $41.23. That is up +27% on the projected 2034 average. Momentum favours further upside here.
Agios Pharmaceuticals, Inc.'s 2040 outlook centres on $355.80, within a $203.87 to $654.27 range. That is up +71% on the projected 2035 average. That marks a +763% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, AGIO could reach as high as $1,762.57, with a base case around $862.85 and support toward $417.45 — roughly +19.9x from $41.23. Momentum favours further upside here.
Investing $1,000 in AGIO today (≈ 24.254184 AGIO) could be worth
$20,927.71
+$19,927.71 (+1993%) by 2050 · US Dollar
Based on the average projected AGIO price of $862.85 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AGIOwould be worth at today's price.
$1,000 invested in AGIO on Jul 10, 2025 (≈ 25.297243 AGIO) would be worth
$1,043.01
+$43.01 (+4.3%) today · 1.04× · US Dollar
Based on a AGIO entry price of $39.53 vs. today's $41.23.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $37.58 | $1,097.13 | +9.7% |
| 1 month ago | $28.88 | $1,427.63 | +42.8% |
| 3 months ago | $32.92 | $1,252.43 | +25.2% |
| 6 months ago | $28.32 | $1,455.86 | +45.6% |
| 1 year ago | $39.53 | $1,043.01 | +4.3% |
| All time (5.0y) ago | $55.91 | $737.44 | -26.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AGIO forecast.
Our base-case forecast reaches $82.00 around 2029.
Implied market cap at $82.00: $4.88B
The multi-year forecast points to a sustained upside for AGIO, with the 2030 average price (avg) at $118.57 delivering an ROI of 169.4% and a bullish sentiment. By 2040, the average rises to $363.70 with an ROI of 726.4%, and by 2050 the average extends to $877.43 with an ROI of 1893.7%, all labeled bullish.
These figures illustrate potential appreciation through the decade and beyond, but they are estimates rather than guarantees and depend on market conditions and execution of the company’s strategy over time.
Tap a question to reveal the answer.
2030 forecast: min $82.51, avg $118.57, max $184.72; ROI 169.4%; sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward with rising averages and ROI: 2027 24.4%, 2028 54.3%, 2029 105.7%, 2030 169.4%, 2031 195.5%, 2032 233.9%, 2033 265.7%, 2034 282.8%, 2035 392.6%, 2040 726.4%, 2050 1893.7%; 2026 is neutral.
Yes. The 2031 max is $208.10 and the 2032 max is $240.81, indicating a crossing above $200 is possible in 2031 or later.
RSI14 is 80 with sentiment BULLISH. SMA50 is $30.42 and SMA200 is $31.78. Support is at $26.51 and resistance at $44.01. The 30-day range is $34.51 to $56.12.
2040 forecast: min $202.61, avg $363.70, max $682.01; ROI 726.4%; sentiment BULLISH.
Agios Pharmaceuticals, Inc. Community Discussion
0Share your Agios Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.